Impact Biomedical Inc. SEC filings IBO
Impact Biomedical Inc. has 146 filings in SEC EDGAR's recent list, going back to Feb 12, 2021. Its latest annual report, Form 10-K, was filed on Mar 11, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 7, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 3, 2026 (regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 425 | Filing | Nov 3, 2026 | — |
| 425 | Filing | Sep 17, 2026 | — |
| 425 | Filing | Sep 15, 2026 | — |
| UPLOAD | Letter from the SEC | Mar 10, 2025 | — |
| CORRESP | Letter to the SEC | Mar 7, 2025 | — |
| UPLOAD | Letter from the SEC | Feb 6, 2025 | — |
| CORRESP | Letter to the SEC | Jan 10, 2025 | — |
| UPLOAD | Letter from the SEC | Dec 20, 2024 | — |
| EFFECT | Filing | Sep 13, 2024 | — |
| CORRESP | Letter to the SEC | Sep 9, 2024 | — |
| CORRESP | Letter to the SEC | Sep 9, 2024 | — |
| CORRESP | Letter to the SEC | Sep 5, 2024 | — |
| CORRESP | Letter to the SEC | Sep 5, 2024 | — |
| CORRESP | Letter to the SEC | Sep 3, 2024 | — |
| CORRESP | Letter to the SEC | Sep 3, 2024 | — |
| 8-A12B/A | Filing | Aug 23, 2024 | — |
| CORRESP | Letter to the SEC | Aug 12, 2024 | — |
| CORRESP | Letter to the SEC | Aug 12, 2024 | — |
| CERT | Nyse american certification | Aug 9, 2024 | — |
| CORRESP | Letter to the SEC | Aug 8, 2024 | — |
| CORRESP | Letter to the SEC | Aug 8, 2024 | — |
| 8-A12B | Filing | Aug 8, 2024 | — |
| UPLOAD | Letter from the SEC | Oct 25, 2023 | — |
| EFFECT | Filing | Aug 4, 2023 | — |
| CORRESP | Letter to the SEC | Aug 2, 2023 | — |
| CORRESP | Letter to the SEC | Jul 24, 2023 | — |
| UPLOAD | Letter from the SEC | Jul 13, 2023 | — |
| CORRESP | Letter to the SEC | Jun 30, 2023 | — |
| UPLOAD | Letter from the SEC | Jun 27, 2023 | — |
| CORRESP | Letter to the SEC | Jun 21, 2023 | — |
| UPLOAD | Letter from the SEC | Jun 9, 2023 | — |
| CORRESP | Letter to the SEC | Jun 2, 2023 | — |
| UPLOAD | Letter from the SEC | May 25, 2023 | — |
| CORRESP | Letter to the SEC | Jan 31, 2023 | — |
| UPLOAD | Letter from the SEC | Jan 20, 2023 | — |
| CORRESP | Letter to the SEC | Jan 9, 2023 | — |
| UPLOAD | Letter from the SEC | Jan 3, 2023 | — |
| CORRESP | Letter to the SEC | Dec 7, 2022 | — |
| UPLOAD | Letter from the SEC | Aug 31, 2022 | — |
| CORRESP | Letter to the SEC | Aug 24, 2022 | — |
| UPLOAD | Letter from the SEC | Aug 11, 2022 | — |
| CORRESP | Letter to the SEC | Aug 2, 2022 | — |
| UPLOAD | Letter from the SEC | Jul 21, 2022 | — |
| CORRESP | Letter to the SEC | Jun 24, 2022 | — |
| UPLOAD | Letter from the SEC | Oct 26, 2021 | — |
| CORRESP | Letter to the SEC | Sep 29, 2021 | — |
| UPLOAD | Letter from the SEC | Feb 24, 2021 | — |
Showing 47 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- IBO (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- West Henrietta, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1834105
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.